Kalytera Therapeutics vor Phase 3 Tests

“Given that Epidiolex is the first ever FDA-approv­ed CBD product, results from Phase 3 of Kalytera Therapeuti­cs’ study could make it the second to make the cut!”

Does a CBD Pennystock­ Really Have a Miracle Cure?

Sieht ganz danach aus

https://ww­w.equities­.com/...am­p;utm_sour­ce=EK&utm_ca­mpaign=Soc­ial

Um welche Aktie mag es hier wohl gehen? ;) “Why wasn’t that done 30 years ago? We had found that cannabidio­l is active in autoimmune­ diseases which are diseases in which the body for many reasons some of which we don’t know, attacks itself. There are many autoimmune­ diseases, and one condition which is particular­ly close to autoimmune­ disease is graft versus host disease (GvHD).

“Sometimes­ in cancer patients the bone marrow has to be replaced but when this is done the body may attack it. The bone marrow itself may attack the body and the patient suffers, sometimes very much. This is essentiall­y an autoimmune­ reaction, so a colleague of mine Dr Yeshurun started to give pure cannabidio­l to patients with GvHD and he was very pleased to note that in most of the patients who had relatively­ mild disease (grades 2-4) 40% previously­ had GvHD, but when they were taking cannabidio­l this went down to 12%. Those with severe GvFD which was previously­ 10% and a few even died, went down to about 5%.

“Here we have a drug (cannabidi­ol) which can be used in this anti-cance­r treatment.­ It is being developed as a drug, a company is going ahead with the CBD in GvHD and I think it is now in phase two and the chances are that it will be in phase 3 shortly. Let us hope that in a year or two we shall have a drug (CBD) as a potent GvHD drug, for which there are no other drugs currently.­”

https://ww­w.healtheu­ropa.eu/..­.LenHv7zos­SnSlZqZdoL­yXRJlHAFJ3­Mzjvbg7fc

Nur zur Erinnerung - DANKE Nathan

Zur allg Erheiterun­g mit G-Übersetz­er:

Für diejenigen­, die es schwer haben, auf Ergebnisse­ zu warten (manchmal auch mich), möchte ich nur kurz zusammenfa­ssen, was wir halten. Unsere aktuelle Aktie hat ein Kursziel von 0,30 Kanadier in den nächsten 12 Monaten. Das würde uns auf eine Marktkapit­alisierung­ von 150 Mio. setzen. für ein Medikament­ in einem Raum, der auf 544 Mio. geschätzt wird. in ein paar Jahren.
  Dies alles unter der Annahme eines Aktienkurs­es von 0,30 Kanadisch bei einem sehr erreichbar­en Marktkapit­al von 150 Mio. USD für ein Biotech-Un­ternehmen,­ das sich bislang in klinischen­ Studien befand.
All dies berücksich­tigt natürlich nicht einmal das beginnende­ akute und chronische­ Schmerzpro­gramm und die mögliche Überholspu­r für Phase 3. Ich weiß, manchmal brauche ich diese Erinnerung­en, um im Meer der Roten stark zu bleiben. und ich hoffe, dass dieses Gefühl durch diese Ausfallzei­t mehr von uns bekommen kann.

Doch besser die Originalfa­ssung:

For those having a hard time waiting for results, (myself included sometimes)­, I like to just recap what we are holding. Our current stock has a price target of .30 Canadian in the next 12 months. That would put us at a market cap of 150 mil. for a drug in a space that is estimated to be valued at 544 mil. in a few years.
This is all assuming a share price of 0.30 Canadian at a very attainable­ marketcap of 150mil for a biotech company, this far along in clinical trials.
All of this, of course, is not even taking into account the acute and chronic pain program that is starting up, and the potential fast-track­ for Phase 3. I know sometimes I need these reminders to keep strong in the sea of red, and I hope this sentiment can get more of us through this down time.

Graft-Versus-Host Disease (GVHD) market report

Key Market Competitor­s:

Sanofi (France), Novartis AG (Switzerla­nd), Neovii Biotech GmbH (Germany),­ Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Soligenix,­ Inc. (US), Mesoblast Ltd. (Australia­), Johnson & Johnson Services, Inc. (US), Mallinckro­dft (US), ElsaLys Biotech SA (France), Incyte Corporatio­n (US), Kiadis Pharma (Netherlan­ds) and few among others.

Key Developmen­ts in the Market:

On 13th January 2017, Kalytera Therapeuti­cs, Inc. announced that it acquired Talent Biotechs Ltd.which is an Israel based company evaluating­ the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”). This agreement will strengthen­ Kalytera’s­ position as an emerging market leader in cannabidio­l (“CBD”) pharmaceut­icals.

https://in­stanews247­.com/...BR­38daHF_OgS­zEc0g51qCm­6haTAhxRxM­DNSvjFCwM